Back grey arrow rt.gif
 
 
FDA updates on valsartan recalls - More Recalls of Generics
 
 
  Download the PDF here
 
Download the PDF here
 
FDA updates on valsartan recalls - More Recalls of Generics https://www.fda.gov/drugs/drugsafety/ucm613916.htm 2 pdfs attached of companies listed by FDA under recall and companies not under recall.
 
"FDA has updated the list of valsartan products under recall and the list of valsartan products not under recall to incorporate recalls of valsartan-containing products manufactured by Hetero Labs Limited, in India, labeled as Camber Pharmaceuticals Inc. Not all Camber valsartan products distributed in the U.S. are being recalled." Update [8/9/2018]
 
Investigation ongoing - statement to be updated as more information is available
 
FDA updates recalled valsartan-containing product information
 
Update [8/9/2018] FDA has updated the list of valsartan products under recall and the list of valsartan products not under recall to incorporate recalls of valsartan-containing products manufactured by Hetero Labs Limited, in India, labeled as Camber Pharmaceuticals Inc. Not all Camber valsartan products distributed in the U.S. are being recalled.
 
Camber Pharmaceuticals is recalling certain valsartan tablets because they contain the impurity N-nitrosodimethylamine (NDMA) in the active pharmaceutical ingredient (API). Hetero Labs manufactures the API for the Camber products using a process similar to Zhejiang Huahai Pharmaceuticals.
 
Test results from Hetero Labs show the amount of NDMA found in its valsartan API exceeds acceptable levels; although it is generally lower than the amount discovered in the API manufactured by Zhejiang.
 
FDA is testing samples of valsartan API and finished products to confirm the extent and amount of NDMA and help inform the ongoing investigation. The agency has also contacted other manufacturers of valsartan API to determine if their manufacturing processes are at risk for the formation of NDMA, and is working with them to ensure NDMA is not present in future valsartan API.
 
Valsartan is an angiotensin II receptor blocker (ARB), and FDA is investigating whether other types of ARBs are at risk for the presence of NDMA.
 
Recalled valsartan products labeled as Camber may be repackaged by other companies. FDA will provide updates as more information becomes available.
 
-------------------------------------------
 
FDA updates recalled valsartan-containing product information and reminds API manufacturers to evaluate processes for unsafe impurities
 
Update [8/2/2018] FDA continues to evaluate valsartan-containing products and has updated the list of products included in the recall and the list of products not included in the recall. In addition to updating the lists, FDA revised information related to A-S Medication on the list of products included in the recall. The agency will continue to provide information when it becomes available.
 
FDA is working with drug manufacturers to ensure future valsartan active pharmaceutical ingredients (APIs) are not at risk of NDMA formation. The agency reminds manufacturers to thoroughly evaluate their API manufacturing processes, and changes to those processes, to detect any unsafe impurities. If a manufacturer detects new or higher levels of impurity, they should take action to prevent changes to the product's safety profile.
 
-------------------------------------------
 
FDA updates recalled valsartan-containing product information
 
Update [7/27/2018] FDA is updating health care professionals and patients after discovering that several additional companies that repackage drug products are also recalling valsartan-containing products.
 
FDA has product recall information from three additional repackagers of valsartan-containing products made by Teva Pharmaceuticals and Prinston Pharmaceuticals Inc. - labeled as A-S Medication Solutions LLC, AvKARE and RemedyRepack - and the agency has added them to the recalled products list. Two of these companies, A-S Medication and RemedyRepack, may also distribute valsartan products not affected by the recall. The agency is confirming this information and will provide an update once it is available.
 
The following additional repackagers are recalling or are expected to recall valsartan-containing products. FDA is working to gather product recall information from these companies and has removed them from the list of products that are not impacted by this recall:
 
o Bryant Ranch Prepack Inc.
o H. J. Harkins Company Inc. (this company was not originally included on either list)
o Lake Erie Medical, doing business as Quality Care Products LLC
o NuCare Pharmaceuticals Inc.
o Northwind Pharmaceuticals
o Proficient Rx
 
It is possible that not all valsartan-containing products repackaged by these companies are impacted by the recall. FDA continues to evaluate valsartan-containing products and will update the list of products included in the recall and the list of products not included in the recall as more information becomes available.
 
----------------------------------------------
 
Analysis of N-nitrosodimethylamine (NDMA) Levels in Recalled Valsartan in the U.S. Update [7/27/2018] On July 13th, FDA announced a recall of certain batches of valsartan tablets because of an impurity, a chemical known as N-nitrosodimethylamine (NDMA). Valsartan is a medication commonly used to treat high blood pressure and heart failure. NDMA has been found to increase the occurrence of cancer in animal studies. These animal studies were done using amounts of NDMA much higher than the impurity levels in recalled valsartan batches. Based on these animal studies, the U.S. Environmental Protection Agency considers NDMA a probable human carcinogen-a chemical that can increase the risk of cancer in humans. NDMA is found in some water supplies and in some foodsi . Consuming up to 96 nanograms NDMA/day is considered reasonably safe for human ingestioni . It is estimated that over the course of a person's lifetime, consuming this amount of NDMA would result in less than one additional case of cancer for every 100,000 people. To put this in context, currently one out of every three people in the US will experience cancer in their lifetime.
 
The amounts of NDMA found in the recalled batches of valsartan exceeded these acceptable levels. The agency wanted to put some context around the actual potential risk posed to patients who used versions of valsartan that may have contained high levels of NDMA. Based on records from the manufacturer of the recalled valsartan, some levels of the impurity may have been in the valsartan-containing products for as long as four years. FDA scientists estimate that if 8,000 people took the highest valsartan dose (320 mg) from the recalled batches daily for the full four years, there may be one additional case of cancer over the lifetimes of these 8,000 people. This assessment led to FDA's decision to have these batches recalled.
 
Patients taking valsartan from a recalled batch should continue taking their current medicine until their doctor or pharmacist provides a replacement or a different treatment option. It is important to know that not all valsartan products contained NDMA, so pharmacists may be able to provide a refill of valsartan medication from batches that that are not affected by the recall, or doctors may prescribe a different medication that treats the same indications.
 
FDA continues to evaluate the safety of valsartan-containing products and will update the list of products included in the recall and the list of products not included in the recall as more information becomes available. If you are taking a valsartan product, be sure to check to back as the lists may change.
 
Average Daily Intake:
 
WATER: (assume 3 to 6 ng N-nitrosodimethylamine/l)(1) 6 to 12 ng; direct intake from drinking water is probably much less than 1 ug/day(2). FOOD: (assume <0.1 to 84 ug/kg)(4) <0.16 to 134 ug. [(1) Kimoto WI et al; Water Res 15: 1099-1106 (1981) (2) USEPA; Ambient Water Quality Criteria Doc: Nitrosamines p.C-14 (1980) EPA 440/5-80-064 (4) IARC; IARC Monographs on the Evaluation of Carcinogenic Risks to Humans 17: 125-76 (1978)] iiThe calculated acceptable intake for NDMA is based on methods described in the ICH Guidance M7(R1) Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk
 
(https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM347725.pdf)
 
------------------------------------
 
FDA publishes a list of valsartan-containing products not part of the recall
 
Update [7/24/2018] FDA is updating health care professionals and consumers on the agency's progress in responding to the ongoing recalls of valsartan, which is used to treat high blood pressure and heart failure, due to the presence of NDMA. The agency has posted a list of valsartan-containing products not impacted by this recall. FDA continues to evaluate valsartan-containing products and will update the list of products included in the recall and the list of products not included in the recall as more information becomes available.
 
Manufacturers of these products often produce multiple dosage strengths, however not all of them are being recalled. FDA recommends health care professionals and patients carefully check these lists. Health care professionals and patients should check this statement frequently for any updates.
 
FDA reminds consumers to continue taking your current medicine until your doctor or pharmacist gives you a replacement or a different treatment option. Untreated hypertension (high blood pressure) leads to an increase in the risk of heart attacks and stroke. Untreated heart failure increases the risk of hospitalization and death.
 
Consumers and health care professionals should continue to report any adverse reactions with valsartan-containing products, to the FDA's MedWatch program to help the agency better understand the scope of the problem:
 
o Complete and submit the report online at www.fda.gov/medwatch/report.htm
o Download and complete the appropriate form, then submit it via fax at
1-800-FDA-0178
 
----------------------------------------------
 
FDA updates health care professionals and patients on recent valsartan recalls [7/18/2018] The U.S. Food and Drug Administration is updating health care professionals and consumers following a recent FDA press releaseabout voluntary recalls of several drug products containing the active pharmaceutical ingredient (API) valsartan. Valsartan is used to treat high blood pressure and heart failure. Not all products containing valsartan are being recalled, and this update will clarify which valsartan-containing products are being recalled.
 
The recalled products contain an impurity, N-nitrosodimethylamine (NDMA), in the API manufactured by Zhejiang Huahai Pharmaceuticals, Linhai, China. The presence of the potentially cancer-causing NDMA was unexpected, and the agency believes the NDMA is related to changes in the way the active substance was manufactured. Some levels of the impurity may have been in the valsartan-containing products for as long as four years. The investigation into valsartan-containing products is ongoing, and the following list may change. We will update this statement as we have more information.
 
There are currently three voluntary recalls related to the NDMA impurity detected in the valsartan API:
 
o Teva Pharmaceuticals USA labeled as Major Pharmaceuticals - recall is at the retail level because these products are only used in facilities where they are directly administered to patients by health care professionals: Valsartan 80 mg and 160 mg products;
 
o Prinston Pharmaceuticals Inc. labeled as Solco Healthcare LLC - recall is at the consumer/user level: Valsartan 40 mg, 80 mg, 160 mg, and 320 mg; and valsartan/HCTZ 80 mg/12.5 mg, 160 mg/12.5 mg, 160 mg/25 mg, 320 mg/12.5 mg, and 320 mg/25 mg products; and
 
o Teva Pharmaceuticals labeled as Actavis LLC - recall is at the consumer/user level: Valsartan 40 mg, 80 mg, 160 mg, and 320 mg; and valsartan/HCTZ 80 mg/12.5 mg, 160 mg/12.5 mg, 160 mg/25 mg, 320 mg/12.5 mg, and 320 mg/25 mg products.
 
Detailed list of products included in the recall (PDF - 87 KB)
 
What should patients know:
 
o Continue taking your current medicine until your doctor or pharmacist gives you a replacement or a different treatment option.
 
o Not all valsartan-containing medications are affected and being recalled.
 
o If you are taking any medication containing valsartan, compare the information on your prescription bottle with the information in this list(company, National Drug Code, lot number) to determine if your current medicine has been recalled. If you are not certain, contact your pharmacist.
 
o If you have medicine included in the recall, contact your pharmacist. The pharmacist may be able to provide you with valsartan made by another company. If not, contact your doctor immediately to discuss other treatment options.
 
What health care professionals should know:
 
o FDA has determined the recalled valsartan products pose an unnecessary risk to patients. Therefore, FDA recommends patients use valsartan-containing medicines made by other companies or consider other available treatment options for the patient's medical condition.
 
o If you have medication samples from these companies, quarantine the products and do not provide them to patients.
 
Consumers and health care professionals should report any adverse reactions with valsartan-containing products, to the FDA's MedWatch program to help the agency better understand the scope of the problem:
 
o Complete and submit the report online at www.fda.gov/medwatch/report.htm
 
o Download and complete the appropriate form, then submit it via fax at 1-800-FDA-0178
 
 
 
 
  iconpaperstack View Older Articles   Back to Top   www.natap.org